Form 4: United Therapeutics Director Exercises Options, Sells Shares

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold 4,560 shares of common stock on September 10, 2025.

Summary

• Tommy G. Thompson, a Director of United Therapeutics Corp (UTHR), engaged in a pre-planned transaction on September 10, 2025.
• Exercised stock options to acquire 4,560 shares of common stock at an exercise price of $229.81 per share.
• Immediately after, sold 4,560 shares of common stock at a price of $403.36 per share.
• The transaction was conducted pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Mr. Thompson directly holds 8,480 shares, indirectly holds 8,200 shares via a Trust, and 5,800 shares via a Family LLC.
• Beneficial ownership also includes 880 shares of common stock to be issued around July 8, 2026, from RSUs vested on July 7, 2023, for which receipt was deferred.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider transaction (option exercise and sale) executed under a pre-planned 10b5-1 program. It is neutral in sentiment as it reflects a standard compensation-related event rather than a significant positive or negative operational or strategic development for the company.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to insider trading rather than opportunistic timing.
• The sale price of $403.36 is significantly higher than the exercise price of $229.81, indicating a profitable transaction for the director.

Negatives

• The sale of shares by a director could be interpreted as a reduction in direct exposure to the company's stock, although it is a common practice for option exercises.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an insider transaction, common across all industries for publicly traded companies when executives or directors exercise options and/or sell shares. It does not provide specific insights into broader industry trends for the pharmaceutical or biotechnology sector.

Related Party Transactions

• The reported transactions involve a director of United Therapeutics Corp, making them related party transactions by definition.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived as a slight negative, but given it is a pre-planned transaction and a common practice for option exercises, the impact is likely minimal. The director still retains significant indirect holdings.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Key Dates

Keywords

United Therapeutics, UTHR, Tommy G Thompson, Director, Insider Trading, Stock Option Exercise, Share Sale, Form 4, SEC Filing, 10b5-1 Plan